Form 4: Bolt Biotherapeutics Director Reprices Stock Options

Bolt Biotherapeutics director Brian O'Callaghan exchanged multiple stock options with high exercise prices for new options at a significantly lower exercise price of $5.44.

Summary

• Director Brian O'Callaghan of Bolt Biotherapeutics, Inc. (BOLT) engaged in a series of option exchanges on December 12, 2025.
• O'Callaghan cancelled six tranches of existing Director Stock Options with original exercise prices ranging from $6.40 to $180.20.
• In exchange, O'Callaghan received six new Director Stock Options, each with an exercise price of $5.44.
• The total number of shares underlying these options remains 7,903, with individual tranches of 1,393, 1,810, 1,250, 1,250, 1,100, and 1,100 shares.
• Five of the new options are fully vested and exercisable.
• One new option for 1,100 shares (originally granted May 27, 2025) vests on the earlier of May 27, 2026, or the day prior to the next annual meeting of stockholders, subject to continuous service, and vests fully upon a change in control.

Sentiment

Score: 3

Explanation: The repricing of director stock options, particularly from very high strike prices to a significantly lower $5.44, strongly suggests substantial past stock price underperformance. While it aims to re-incentivize the director, it reflects a negative historical trend for the company's equity value.

Positives

• The repricing of options can re-incentivize management and directors by making their equity awards valuable again, potentially aligning their interests with future stock price recovery.

Negatives

• Option repricing typically occurs when the company's stock price has significantly underperformed, rendering previous options underwater, which indicates past poor stock performance.
• Shareholders may view option repricing negatively as it effectively grants new value to insiders at a lower strike price, potentially diluting existing shareholder value if the stock recovers.
• The significant reduction in exercise prices (e.g., from $180.20 to $5.44) highlights a substantial decline in the company's stock value since the original grants.

Risks

• Shareholder dissatisfaction and potential governance concerns regarding executive compensation practices, especially if the repricing is not tied to performance hurdles.
• Continued poor stock performance could render even the repriced options underwater again.
• The need for repricing suggests a challenging operational or market environment for Bolt Biotherapeutics.

Future Outlook

The repricing of director stock options aims to re-align incentives for future performance, particularly given the vesting conditions tied to continuous service and a change in control for one tranche of options.

Management Comments

• Director Brian O'Callaghan agreed to the cancellation of six previously granted stock options.
• O'Callaghan accepted new options with a significantly reduced exercise price of $5.44 in exchange for the cancelled options.

Industry Context

Option repricing is a common practice in industries, particularly biotechnology, where stock prices can be highly volatile due to clinical trial results, regulatory approvals, and market sentiment. When a company's stock price falls significantly, options granted at higher prices become 'underwater,' losing their incentive value. Repricing aims to restore this incentive, though it can be controversial among shareholders.

Comparison to Industry Standards

• Option repricing is generally viewed with caution by corporate governance experts and institutional investors, as it can be perceived as a 're-do' for management and directors at the expense of shareholders who have borne the brunt of the stock price decline.
• While not uncommon in volatile sectors like biotech, best practices often suggest linking repricing to new performance conditions or a significant time delay to mitigate shareholder concerns.
• Compared to companies with strong stock performance, repricing indicates a need to re-motivate leadership due to past underperformance, which is a negative signal.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative perception due to the repricing of options, which can be seen as dilutive or as rewarding management despite poor stock performance. However, it could also be viewed as a necessary step to retain and motivate key directors.
• Director (Brian O'Callaghan): Re-incentivized with options that are now 'in-the-money' or closer to it, providing renewed motivation for future performance.
• Employees: May impact morale if other employees' options are also underwater and not repriced, or if they perceive a disconnect in compensation practices.

Next Steps

• The 1,100 share option granted on December 12, 2025, will vest on the earlier of May 27, 2026, or the day immediately prior to the next annual meeting of stockholders.
• Full vesting of the 1,100 share option will occur upon a change in control of the Issuer.

Key Dates

Recommendation

The repricing of director stock options from significantly higher prices to $5.44 indicates substantial past stock price underperformance for Bolt Biotherapeutics. While this action aims to re-incentivize the director, it reflects a challenging historical period for the company's equity. Investors should 'hold' to assess whether this re-incentivization, coupled with any operational or strategic changes, leads to a turnaround in the company's performance and stock value. Further analysis of the company's fundamentals and future outlook is warranted.

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, Stock Options, Option Repricing, Director Compensation, Insider Trading, Equity Awards, Corporate Governance, Biotechnology